Table 1.
Baseline Characteristics of the Cryopreserved and Fresh Cohorts
| Characteristic | N* | Cryopreserved (N = 30) | Fresh (N = 60) | P Value† |
|---|---|---|---|---|
| Patient age, yr, mean | 90 | 56 | 57 | .74 |
| Donor age, yr, mean | 87 | 34 | 41 | .017 |
| Sex, n/N (%) | 90 | .11 | ||
| Female | 17/30 (57) | 22/60 (37) | ||
| Male | 13/30 (43) | 38/60 (63) | ||
| Karnofsky Performance Scale, n/N | 88 | .006 | ||
| ≥90 | 13/29 | 16/59 | ||
| <90 | 16/29 | 43/59 | ||
| Graft type, n/N (%) | 90 | .28 | ||
| Allogeneic | 27/30 (90) | 47/60 (78) | ||
| Haploidentical | 3/30 (10) | 13/60 (22) | ||
| Donor type, n/N (%) | 90 | .003 | ||
| HLA-identical sibling | 2/30 (6.7) | 20/60 (33) | ||
| HLA-matched unrelated | 22/30 (73) | 25/60 (42) | ||
| HLA-haploidentical | 3/30 (10) | 13/60 (22) | ||
| HLA-mismatched unrelated | 3/30 (10) | 2/60 (3.3) | ||
| Conditioning intensity, n/N (%) | 90 | .81 | ||
| MAC | 9/30 (30) | 21/60 (35) | ||
| RIC | 21/30 (70) | 39/60 (65) | ||
| CMV risk group, n/N (%) | 90 | .17 | ||
| High (R+) | 18/30 (60) | 47/60 (78) | ||
| Intermediate (R-, D+) | 4/30 (13) | 3/60 (5) | ||
| Low (R-, D-) | 8/30 (27) | 10/60 (17) | ||
| ABO match, n/N (%) | 90 | .033 | ||
| Matched | 16/30 (53) | 42/60 (70) | ||
| Minor mismatch | 11/30 (37) | 7/60 (12) | ||
| Major mismatch | 3/30 (10) | 10/60 (17) | ||
| Bidirectional | 0/30 (0) | 1/60 (1.7) | ||
| Disease type, n/N (%) | 90 | .34 | ||
| Myeloid | 23/30 (77) | 52/60 (87) | ||
| Lymphoid | 6/30 (20) | 6/60 (10) | ||
| Mixed | 1/30 (3.3) | 2/60 (3.3) | ||
| DRI, n/N (%) | 90 | .18 | ||
| High | 12/30 (40) | 18/60 (30) | ||
| Intermediate | 17/30 (57) | 42/60 (70) | ||
| Low | 1/30 (3.3) | 0/60 (0) | ||
| CD34 dose, × 106/kg, mean | 90 | 7.4 | 9.3 | .034 |
| CD3 dose, × 108/kg, mean | 89 | 3.1 | 2.56 | .061 |
R indicates recipient; D, donor.
⁎
Number of patients with available data.
†
Statistical test performed: t test, chi-square test of independence, Fisher's exact test.